Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | June 05, 2026 | June 09, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Sr. VP Fince-Global Controller | May 03, 2023 | May 05, 2023 |
| Organon & Co.OGN · Entity 4115 | Director | May 07, 2021 | May 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 30,000 · Balance 30,000 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2036-06-05 | Direct | 60,000 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 60,000 · Balance 60,000 F2: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
F2: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
Merck & Co., Inc.
Report date May 03, 2023 · Filed May 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,709.972 |
Ending reported balance
After 2023-05-04 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2023-05-03 · Exercise / conversion · Acquired 803 · Balance 45,362.972 Row 2 · 2023-05-03 · Tax withholding · Disposed 276 · Balance 45,086.972 Row 3 · 2023-05-04 · Exercise / conversion · Acquired 949 · Balance 46,035.972 Row 4 · 2023-05-04 · Tax withholding · Disposed 326 · Balance 45,709.972 Row 5 · 2023-05-04 · Exercise / conversion · Acquired 15,875 · Balance 61,584.972 Row 6 · 2023-05-04 · Sale · Disposed 15,875 · Balance 45,709.972 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.5000 to $117.6200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2025-05-03 | Direct | 1,608 |
Reported balance
After 2023-05-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-05-03 · Exercise / conversion · Disposed 803 · Balance 1,608 F2: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2024-05-04 | Direct | 951 |
Reported balance
After 2023-05-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-05-04 · Exercise / conversion · Disposed 949 · Balance 951 F2: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.07 · Expires 2027-05-04 | Direct | 0 |
Reported balance
After 2023-05-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-05-04 · Exercise / conversion · Disposed 15,875 · Balance 0 F5: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.5000 to $117.6200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F3: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025.
F4: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.
F5: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.
Organon & Co.
Report date May 07, 2021 · Filed May 07, 2021
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 3,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-15-011277 · doc4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,007 Underlying: Common Stock · 3,007 shares Expires 2018-05-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 27,510 | $0.00 Strike: $58.22 | $0.00 |
DisclosureSEC source: 0001225208-14-012822 · doc4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,510 Underlying: Common Stock · 27,510 shares Expires 2024-05-08 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning May 9, 2015. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 2,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-012822 · doc4.xml · derivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,576 Underlying: Common Stock · 2,576 shares Expires 2017-05-09 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 4,240 | $58.22 | $246,852.80 |
DisclosureSEC source: 0001225208-14-012269 · doc4.xml · derivative · entry 3 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,240 shares Expires 2014-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,579 | $58.22 | $91,929.38 |
DisclosureSEC source: 0001225208-14-012269 · doc4.xml · nonDerivative · entry 2 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,419.566 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:02 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 4,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-012269 · doc4.xml · nonDerivative · entry 1 Karachun Rita A · CIK 0001601572 · Sr. VP Fince-Global Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,998.566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.